Clinical Scorecard: 4DMT Completes Enrollment in Gene Therapy Trial for Wet AMD
At a Glance
| Category | Detail |
|---|---|
| Condition | Wet Age-Related Macular Degeneration (AMD) |
| Key Mechanisms | Gene therapy using an adeno-associated virus vector to deliver aflibercept and anti-VEGF-C components. |
| Target Population | Treatment-naïve patients with wet AMD. |
| Care Setting | Multicenter, randomized, double-masked clinical trial. |
Key Highlights
- Enrollment completed for phase 3 trial 4FRONT-1.
- Comparing 4D-150 with aflibercept (Eylea) administered every 8 weeks.
- Primary endpoint: noninferiority in best-corrected visual acuity at 52 weeks.
- Secondary endpoint: reduction in treatment burden of aflibercept injections.
- Top-line data expected in the first half of 2027.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of wet AMD based on clinical examination and imaging.
Management
- Consider gene therapy with 4D-150 as a treatment option.
Monitoring & Follow-up
- Monitor best-corrected visual acuity and treatment burden.
Risks
- Potential need for supplemental aflibercept injections.
Patient & Prescribing Data
Treatment-naïve patients with wet AMD.
4D-150 aims to provide sustained intraocular anti-VEGF expression.
Clinical Best Practices
- Utilize a randomized, controlled trial design for evaluating new therapies.
- Ensure comprehensive patient monitoring for visual acuity and treatment response.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
